Please login to the form below

Not currently logged in

Pfizer/ S-A vaccines halted in Japan

Separate vaccines from sanofi-aventis and Pfizer have had their use suspended in Japan following the deaths of four children

Separate vaccines from sanofi-aventis (S-A) and Pfizer have had their use suspended in Japan following the deaths of four children.

S-A's ActHIB, to protect against Haemophilus influenzae type b, and Pfizer's Prevenar to prevent against pneumococcal disease such as pneumonia and meningitis, have been suspended by Japan's Health Ministry while the causes of deaths of four inoculated children are investigated.

According to the Associated Press, four children, age 2 years old or under, died between March 2 and March 4, with the deaths occurring within a three day period of the vaccines administration.

Over one million children have been inoculated in Japan since ActHIB was launched in the country in December 2008 and Prevenar started to be used in 2009.

The suspension follows a 2009 incident where authorities suspended the use of a batch of Prevenar in the Netherlands after the deaths of three children inoculated with the vaccine.

Authorities later decided there was no correlation between the deaths and the vaccinations.

7th March 2011


COVID-19 Updates and Daily News

Featured jobs


Add my company

Triducive are a strategic healthcare consultancy who produce communications that have practical, dynamic application that encourage behaviour change because of the...

Latest intelligence

How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
Deep 6 AI: the smart software breathing new life into clinical trials
Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....
COVID-proof: How Teams are Creating Launch Intensity thru Adversity
Now that the game has changed, how are marketers shifting their launch behaviour? We've identified 5 common observations from effective teams....